Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) to investigate the application feasibility of circular RNA technology within a specific therapeutic area. This collaboration aims to capitalize on Circode Bio’s proprietary circular RNA technology platform and BMS’s extensive expertise and experience in the pharmaceutical industry, thereby enhancing the understanding of drug development using circular RNA technology.
Circular RNA (CircRNA) is a type of covalently closed endogenous biomolecule characterized by its tissue-specific and cell-specific expression patterns in eukaryotes. Its biogenesis is regulated by specific cis-acting elements and trans-acting factors. When compared to linear RNA, circular RNA exhibits superior stability and lower immunogenicity, which confers significant advantages in therapeutic applications. This partnership follows a similar agreement Circode Bio established with Pfizer in July of the previous year, as reported by the relevant agency.
This strategic collaboration underscores the growing interest in circular RNA as a promising modality for drug development and highlights the potential for novel therapeutics in the pharmaceutical industry.- Flcube.com
